ENTX (Entera Bio) ROCE %: -111.72% (As of Mar. 2026)


ENTX Entera Bio Ltd ENTX
23 GF Score
Price $1.55
! 2 Warning Signs
View Full Analysis

What is Entera Bio ROCE %?

Entera Bio ENTX 23 ROCE % is -111.72% as of Mar. 2026. GuruFocus rates ENTX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Entera Bio's annualized ROCE % for the quarter that ended in Mar. 2026 was -111.72%.

Entera Bio  (NAS:ENTX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Entera Bio ROCE % Related Terms

Entera Bio ROCE % Historical Data

* Premium members only.

The historical data trend for Entera Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entera Bio ROCE % Chart

Entera Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -79.57 -75.22 -79.17 -101.49 -104.79

Entera Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -72.73 -56.47 -77.39 -82.14 -111.72
ENTX
23GF Score
Entera Bio Ltd ENTX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entera Bio ROCE % Calculation

Entera Bio's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-11.529/( ( (9.39 - 1.176) + (15.993 - 2.203) )/ 2 )
=-11.529/( (8.214+13.79)/ 2 )
=-11.529/11.002
=-104.79 %

Entera Bio's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-14.156/( ( (15.993 - 2.203) + (13.129 - 1.576) )/ 2 )
=-14.156/( ( 13.79 + 11.553 )/ 2 )
=-14.156/12.6715
=-111.72 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -111.72% mean?
Entera Bio (ENTX) has a ROCE % of -111.72% as of Mar. 2026.
Is Entera Bio's ROCE % too high?
Entera Bio's current ROCE % is -111.72%. Overall, Entera Bio has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's ROCE % compare to IMA and MNOV?
Entera Bio's ROCE % of -111.72% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Entera Bio's current ROCE % is -111.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Entera Bio (ENTX) has a current ROCE % of -111.72%. The current ROCE % is -111.72%. Entera Bio's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Entera Bio (ENTX), the current ROCE % is -111.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entera Bio Business Description

Other Exchanges 5DT:Germany
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
23GF Score

Get the complete analysis for ENTX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price